Sarepta and Arrowhead Pharmaceuticals Announce Global Licensing Agreement for siRNA Programs

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Under this agreement, Sarepta will gain exclusive global rights to several…

Read MoreSarepta and Arrowhead Pharmaceuticals Announce Global Licensing Agreement for siRNA Programs

Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at RSNA 2024

Median Technologies (FR0011049824, ALMDT), a leading innovator in the development of artificial intelligence (AI)-powered medical devices for early cancer detection, is set to attend the Radiological Society of North America (RSNA) 2024 Annual Meeting, scheduled to take place in Chicago,…

Read MoreMedian Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at RSNA 2024

Exelixis Provides Regulatory Update on Cabozantinib (CABOMETYX®) for Advanced Neuroendocrine Tumors

Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) has scheduled a discussion of the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. The sNDA…

Read MoreExelixis Provides Regulatory Update on Cabozantinib (CABOMETYX®) for Advanced Neuroendocrine Tumors

Successful U.S. Remote Robotic Surgery Demo Completed with Virtual Incision, Sovato, City of Hope, and UIC

Virtual Incision, the developer of the MIRA Surgical System, and Sovato Health, the world’s only solution for enabling remote surgery, have announced the successful completion of a preclinical demonstration involving nearly 40,000 miles of combined distance. Four surgeons performed 20…

Read MoreSuccessful U.S. Remote Robotic Surgery Demo Completed with Virtual Incision, Sovato, City of Hope, and UIC

Menarini Group Presents New Data on ORSERDU® (Elacestrant) for ER+, HER2- Advanced Metastatic Breast Cancer at 2024 SABCS

The Menarini Group, a global leader in pharmaceuticals and diagnostics, along with its subsidiary Stemline Therapeutics, will present new and expanded data on ORSERDU® (elacestrant) at the 2024 San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. The company…

Read MoreMenarini Group Presents New Data on ORSERDU® (Elacestrant) for ER+, HER2- Advanced Metastatic Breast Cancer at 2024 SABCS

BioIntelliSense Study Shows Early Detection of Patient Deterioration with FDA-cleared BioButton® Device

BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, today announced the publication of peer-reviewed research in the Journal of Clinical Medicine. The study, titled “A Retrospective Observational Study of Continuous Wireless Vital Sign Monitoring via a Medical Grade…

Read MoreBioIntelliSense Study Shows Early Detection of Patient Deterioration with FDA-cleared BioButton® Device

Trustwise, Hitachi, and Partners Launch MedAssist GPT for Medical Education

Trustwise, an AI performance and risk management innovator, has partnered with Health Innovation Kent Surrey Sussex (Health Innovation KSS), Hitachi Digital Services, and Further to co-develop MedAssist GPT, a generative AI application designed to enhance medical education. The tool, leveraging…

Read MoreTrustwise, Hitachi, and Partners Launch MedAssist GPT for Medical Education

Foresight Diagnostics to Present CLARITY™ MRD Data at 2024 San Antonio Breast Cancer Symposium

Foresight Diagnostics (Foresight) today revealed new data from its ultra-sensitive Foresight CLARITY™ minimal residual disease (MRD) platform in early-stage breast cancer, which will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) later this month. Foresight Diagnostics and…

Read MoreForesight Diagnostics to Present CLARITY™ MRD Data at 2024 San Antonio Breast Cancer Symposium

Vaxxas Expands Global IP for Exclusive Needle-Free Vaccine Manufacturing and Sales

Vaxxas, a clinical-stage biotech company, has broadened its global intellectual property portfolio to include 42 patents, reinforcing its exclusive rights to manufacture and sell its proprietary high-density microarray patch (HD-MAP) vaccination technology across the United States, Europe, Asia, and Australia.…

Read MoreVaxxas Expands Global IP for Exclusive Needle-Free Vaccine Manufacturing and Sales

Meridian Health Plan and Liberty Bank Launch Small Business Loan Program in Illinois

Meridian Health Plan of Illinois, a leading provider of government-sponsored managed care services, has announced a strategic partnership with Liberty Bank and Trust to create a small business loan program aimed at empowering diverse and minority-owned businesses in Illinois. This…

Read MoreMeridian Health Plan and Liberty Bank Launch Small Business Loan Program in Illinois

HCA Healthcare Collects Record 21,137 Pounds of Medication in Sixth Annual ‘Crush the Crisis

HCA Healthcare, Inc. (NYSE:HCA), one of the largest healthcare providers in the United States, proudly announced the success of its sixth annual “Crush the Crisis” national prescription drug take-back day, collecting a record-breaking 21,137 pounds of unused or expired medications.…

Read MoreHCA Healthcare Collects Record 21,137 Pounds of Medication in Sixth Annual ‘Crush the Crisis